Studies
| Closed Clinical Trials | ||
|---|---|---|
|
The ACTIV3 study is testing if monoclonal antibody treatments -- laboratory-made proteins that mimic the immune system’s abilities -- improve recovery from patients hospitalized due to COVID-19. |
5 | https://clinicaltrials.gov/ct2/show/NCT04501978 |
|
The ACTIV3b study is testing if treatments improve recovery from patients hospitalized due to COVID-19. |
19 | https://www.clinicaltrials.gov/ct2/show/NCT04843761?term=TESICO&draw=2&rank=1 |
|
The ACTIV3c study is testing the optimal timing and number of mRNA vaccinations for patients recovering from a COVID-19 infection. |
22 | https://www.clinicaltrials.gov/ct2/show/NCT04969250?term=VATICO&draw=2&rank=1 |
|
The ACTIV4 Host Tissue platform is testing if treatments targeting the host-tissue response to SARS-CoV-2 infection can improve recovery and prevent worsening in patients hospitalized with COVID-19. |
20 | https://clinicaltrials.gov/ct2/show/NCT04924660?term=NCT04924660&draw=2&rank=1 |
|
The ACTIV4A Inpatient study is testing if treatments that aim to prevent blood vessel injuries and blood clots improve recovery from patients hospitalized due to COVID-19. |
3 | https://clinicaltrials.gov/ct2/show/NCT04505774 |
|
The ACTIV4B Outpatient study is testing if anticoagulation agents – blood thinners -- prevent mild infection, being treated at home, from worsening and requiring hospitalization. |
4 | https://clinicaltrials.gov/ct2/show/NCT04498273 |
|
The ACTIV4c Post-Discharge study is testing if anticoagulation agents – blood thinners – improve recovery from COVID-19 for individuals after being discharged from the hospital. |
8 | https://clinicaltrials.gov/ct2/show/NCT04650087 |
|
The C3PO study is testing if convalescent plasma -- the liquid portion of blood collected from patients who have recovered from COVID-19 – prevents mild infection, being treated at home, from worsening and requiring hospitalization. |
1 | https://clinicaltrials.gov/ct2/show/NCT04355767 |